表紙
市場調査レポート

禁煙補助薬:世界市場の見通し

Smoking Cessation Drugs: World Market Prospects 2013-2023

発行 Visiongain Ltd 商品コード 243886
出版日 ページ情報 英文 138 pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=141.49円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
禁煙補助薬:世界市場の見通し Smoking Cessation Drugs: World Market Prospects 2013-2023
出版日: 2013年09月26日 ページ情報: 英文 138 pages
概要

当レポートでは、世界の禁煙補助薬市場の将来的可能性に焦点を当てながら、収益とトレンドなどについて、世界市場/サブマーケット/製品/主要国別に分析/予測し、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリ

第2章 禁煙:イントロダクション

  • タバコ
  • 喫煙関連の健康障害
  • ニコチン中毒
  • 禁煙

第3章 世界の禁煙補助薬市場

  • 禁煙市場の今後の発展動向
  • 販売種類別の禁煙補助薬市場
  • 作用機序別の禁煙補助薬

第4章 禁煙補助薬の主要国市場

  • 禁煙業界の主な地域別市場
  • 米国
  • 日本
  • EUトップ5か国
  • BRIC諸国
    • ブラジル
    • ロシア
    • インド
    • 中国

第5章 主要禁煙製品:今後の展望

  • トップ5のブランド
  • ニコチン置換療法
  • Champix/Chantix (Varenicline, Pfizer)
  • Zyban (Bupropion, GSK)
  • Tabex
  • その他の禁煙補助製品

第6章 禁煙製品のR&Dパイプライン分析

  • ニコチンワクチン:誇大宣伝、あるいは希望?
  • モノアミン酸化酵素阻害薬
  • カンナビノイド受容体1拮抗薬
  • ドーパミンD3 拮抗薬
  • オピエード拮抗薬
  • ARD-1600 (Aradigm)
  • EMB-001 (Embera NeuroTherapeutics)
  • Meclizine (Duke University/Philip Morris Products)
  • その他開発中の禁煙補助製品

第7章 禁煙業界と市場:定質的分析

  • 禁煙補助市場は4社独占状態、しかしいつまで続くか?
  • 禁煙市場のSWOTおよびSTEP分析
    • 禁煙業界の強み
    • 禁煙業界の弱み
    • 禁煙業界の機会
    • 禁煙業界への脅威

第8章 研究についてのインタビュー

  • Dr Vladimir Kosev, Director Strategic Business Development, Sopharma
  • Mr Rick Stewart, CEO, Extab Corporation
  • Mr Trevor Van Meirlo, CEO, Evolution Health Systems
  • Dr Peter Hajek, Director of Tobacco Dependence Research Unit, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, University of London

第9章 調査結果

  • 喫煙は世界における回避可能な死亡の主要原因
  • 禁煙補助薬には有望な治療/商業的可能性がある
  • 世界の禁煙市場:今後の見通し
  • 市場発展要因
  • 主要/新興禁煙市場
  • 結論

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Anti-smoking drug revenues will expand - you see what's most likely to succeed

How much revenue can medicines to treat smoking generate? Visiongain's updated report gives you predictions, helping you stay ahead. There you see financial results, R&D trends, opportunities, and commercial potential.

In that new study you discover forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess technologies, competition, and expected developments for treating tobacco addiction. Find prospects there.

Read on to explore those products and see what their future market could be worth.

Forecasts from 2013-2023 and other analyses to help you find opportunities

Besides revenue forecasting to 2023, our analysis shows recent results, growth rates, and market shares. There you discover original analysis, seeing commercial outlooks and developments (R&D). You also get 60 tables, 36 charts, and four interviews.

Discover what's happening in that industry, using our report to find data you need

In that study you hear what's happening for smoking medications, learning where needs and money exist. Try our report now, seeing how you and your organisation can gain.

Avoid falling behind, missing business or losing influence. Instead, discover information you need to stay ahead. Our work explains, helping your research, analyses, and decisions.

The following sections, then, show what you get in that new investigation.

Sales predictions for the world market and submarkets

Discover in our report overall world revenue to 2023 for smoking-cessation drugs. You also find individual revenue forecasts for therapeutic submarkets at world level:

  • Over-the-counter medicines (OTC)
  • Prescription drugs (Rx)
  • Nicotine replacement therapies (NRT)
  • Nicotine receptor partial agonists (NRPA)
  • Antidepressants.

How will sales of those therapies expand? Which classes of treatments will generate most money? There you assess prospects for revenue growth, seeing where you can benefit.

You also discover sales predictions by agent, seeing how they can succeed.

Revenue predictions for top products - see what's possible

How will those anti-addiction medicines perform to 2023 at world level? Our report forecasts individual revenues of six leading brands:

  • Champix/Chantix
  • NiQuitin/Nicabate/NicoDerm CQ
  • Nicorette
  • Nicotinell
  • Zyban
  • Tabex.

There, from 2013, you discover how high sales can go. Investigate opportunity. You see what's happening, then, understanding challenges, trends, competitors, and opportunities.

You find geographical revenue predictions too.

National markets - where will highest revenues and growth occur?

In developed and developing countries, anti-smoking therapy will give opportunities to pharmaceutical companies. You see where and how, from 2013, understanding potential.

In our study you find individual revenue forecasts to 2023 for 11 national markets:

  • United States (US)
  • Japan
  • EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
  • BRIC countries - Brazil, Russia, India, and China.

There you find countries with highest revenues and potential sales growth. Our work explains. You see the future of those products, appraising progress and discovering what it means, including emerging trends.

Issues affecting developers, producers, and sellers of anti-smoking medicines

The report explains forces affecting that industry and market from 2013, including these:

  • Nicotine vaccines
  • Monoamine oxidase inhibitors
  • Cannabinoid receptor-1 antagonists
  • Dopamine D3 antagonists
  • Opiate antagonists
  • Other smoking cessation aids in testing.

There you assess research and development (R&D), finding advances and outlooks for business. You also explore OTC switching and governmental support of medicines treating tobacco use, including their reimbursement. Discover what the present and future hold.

Companies and overall 2017 market value - how high can sales go?

From 2013, treatments for cigarette smoking hold potential for investments, medical advances, and higher revenues. Our work predicts the overall world market will reach $2.5bn in 2017, with further expansion to 2023.

That report shows you what technologies and organisations hold greatest potential. In particular, you explore these companies:

  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • Novartis.

Examine rising players, too, including Celtic Pharma, Selecta Biosciences, Aradigm, Extab Corporation, and Embera NeuroTherapeutics. Also, find interviews with three companies.

See what's possible in that industry. Our investigation explains the potential of its market, helping you stay ahead.

Information found nowhere else - discover the future of those neurological treatments

Through knowledge such as this, our new report helps you get recognition for insight:

  • Revenues to 2023 at world level, with forecasting of 5 submarkets and 6 products - explore prospects for investments and sales
  • Forecasts to 2023 for 11 national markets in the Americas, Europe, and Asia - investigate countries for revenues and expected growth
  • Prospects for companies - assess portfolios, results, R&D activities, and outlooks for future success.

Smoking Cessation Drugs: World Market Prospects 2013-2023 gives independent analysis. There you receive competitive intelligence found only in our work. That study helps you find the money and show your authority on those technologies and their potentials. Gain now.

Anti-smoking agents - find commercial outlooks by ordering now

Our new report is for everyone investigating treatments for the central nervous system (CNS) and addictions. There you discover revenue forecasts to 2023, with discussions. Avoid missing out - please order now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Executive Summary

  • 1.1. Smoking Cessation Drugs: World Market Overview
  • 1.2. Aims and Format of the Report
  • 1.3. Research and Analysis Methods
  • 1.4. Scope of the Report

2. Introduction to Smoking Cessation

  • 2.1. Tobacco- What is All the Fuss About?
    • 2.1.1. How is Tobacco Consumed?
    • 2.1.2. Tobacco Smoking is a Major Challenge for Healthcare Worldwide
  • 2.2. Smoking Causes Many Health Disorders
  • 2.3. Nicotine Addiction is at the Root of Smoking
  • 2.4. Smoking Cessation
    • 2.4.1. Why is it Difficult to Stop Smoking?
    • 2.4.2. How Can Smokers Quit?

3. World Smoking Cessation Drugs Market, 2013-2023

  • 3.1. How Will the Smoking Cessation Market Develop Until 2023?
  • 3.2. Smoking Cessation Drugs Market by Type of Sale
    • 3.2.1. Over-the-Counter (OTC) Smoking Cessation Drugs, 2012
      • 3.2.1.1. OTC Smoking Cessation Drugs: Forecast, 2013-2023
    • 3.2.2. Prescription (Rx) Smoking Cessation Drugs, 2012
      • 3.2.2.1. Prescription Smoking Cessation Drugs: Forecast, 2013-2023
  • 3.3. Smoking Cessation Drugs by Mechanism of Action
    • 3.3.1. Nicotine Replacement Therapy
      • 3.3.1.1. Nicotine Replacement Therapy, 2012
      • 3.3.1.2. Nicotine Replacement Therapy Forecast, 2013-2023
    • 3.3.2. Nicotine Receptor Partial Agonist Drugs
      • 3.3.2.1. Nicotine Receptor Partial Agonist Drugs, 2012
      • 3.3.2.2. Nicotine Receptor Partial Agonist Drugs Forecast, 2013-2023
    • 3.3.3. Antidepressants
      • 3.3.3.1. Antidepressants for Smoking Cessation, 2012
      • 3.3.3.2. Antidepressants for Smoking Cessation: Forecast, 2013-2023

4. Leading National Markets for Smoking Cessation Drugs to 2023

  • 4.1. Major Geographical Markets for the Smoking Cessation Industry in 2012
  • 4.2. The US is Still the Market Leader
    • 4.2.1. Smoking Prevalence Declining in the US
    • 4.2.2. Availability and Reimbursement of Smoking Cessation Aids in the US
    • 4.2.3. US Smoking Cessation Market Revenue, 2012
    • 4.2.4. US Smoking Cessation Market Forecast, 2013-2023
    • 4.2.5. Scope for US Smoking Cessation Market Expansion
  • 4.3. The Japanese Smoking Cessation Market has Potential to Expand in Revenues
    • 4.3.1. Japan has a Less Developed Smoking Cessation Market
    • 4.3.2. The Japanese Smoking Cessation Market, 2012
    • 4.3.3. Japanese Smoking Cessation Market Forecast, 2013-2023
  • 4.4. The EU-5 Smoking Cessation Drugs Market
    • 4.4.1. The UK Smoking Cessation Market
      • 4.4.1.1. Tobacco Use in the UK
      • 4.4.1.2. The UK Pioneers Smoking Cessation Reimbursement and General Sales OTC Retailing of NRT
      • 4.4.1.3. The UK has Strong Anti-Smoking Legislation
      • 4.4.1.4. UK Smoking Cessation Market, 2012
      • 4.4.1.5. UK Smoking Cessation Market Forecast, 2013-2023
    • 4.4.2. The French Smoking Cessation Market
      • 4.4.2.1. Tobacco Use in France is Still High
      • 4.4.2.2. The French Smoking Cessation Market, 2012
      • 4.4.2.3. French Smoking Cessation Market Forecast, 2013-2023
      • 4.4.2.4. Factors Influencing the Development of the French Market
    • 4.4.3. The Spanish Smoking Cessation Market
      • 4.4.3.1. Tobacco Use in Spain is Low
      • 4.4.3.2. The Spanish Smoking Cessation Market, 2012
      • 4.4.3.3. The Spanish Smoking Cessation Market Forecast, 2013-2023
      • 4.4.3.4. Spain's Anti-smoking Laws are Very Robust
    • 4.4.4. The Italian Smoking Cessation Market
      • 4.4.4.1. Reducing Tobacco Use in Italy is a Government Priority
      • 4.4.4.2. The Italian Smoking Cessation Market, 2012
      • 4.4.4.3. The Italian Smoking Cessation Market Forecast, 2013-2023
      • 4.4.4.4. Italy has a Decades-Long Commitment to Reducing Smoking
    • 4.4.5. The German Smoking Cessation Market
      • 4.4.5.1. Germany is a Smoker's Citadel
      • 4.4.5.2. The German Smoking Cessation Market, 2012
      • 4.4.5.3. German Smoking Cessation Market Forecast, 2013-2023
      • 4.4.5.4. Germany Has a Relaxed Attitude to Smoking
  • 4.5. The BRIC Smoking Cessation Drugs Market is Untapped
    • 4.5.1. The Brazilian Smoking Cessation Market
      • 4.5.1.1. Tobacco Use in Brazil is Pervasive
      • 4.5.1.2. The Brazilian Smoking Cessation Market, 2012
      • 4.5.1.3. Brazilian Smoking Cessation Market Forecast, 2013-2023
      • 4.5.1.4. Smoking Cessation Market Prospects in Brazil Look Bright
    • 4.5.2. The Russian Smoking Cessation Market
      • 4.5.2.1. Tobacco Use in Russia Forms a Serious Problem
      • 4.5.2.2. The Russian Smoking Cessation Market, 2012
      • 4.5.2.3. Russian Smoking Cessation Market Forecast, 2013-2023
      • 4.5.2.4. The Russian Government has started to Take Positive Steps
    • 4.5.3. The Indian Smoking Cessation Market: Vast Possibilities
      • 4.5.3.1. India's Attitudes to Tobacco
      • 4.5.3.2. The Indian Smoking Cessation Market, 2012
      • 4.5.3.3. Indian Smoking Cessation Market Forecast, 2013-2023
      • 4.5.3.4. Indian Smoking Cessation Market Still in its Infancy
      • 4.5.3.5. Prospects for Growth of the Indian Smoking Cessation Market
    • 4.5.4. The Chinese Smoking Cessation Market
      • 4.5.4.1. Tobacco use in China is Unprecedented
      • 4.5.4.2. The Chinese Smoking Cessation Market, 2012
      • 4.5.4.3. Chinese Smoking Cessation Market Forecast, 2013-2023
      • 4.5.4.4. The Chinese Smoking Cessation Market is Under Developed
      • 4.5.4.5. China's Economic Progress Could be Hindered by Tobacco Use

5. Leading Smoking Cessation Products: Outlook to 2023

  • 5.1. The Top 5 Brands Claimed Most of the Market in 2012
  • 5.2. Nicotine Replacement Therapy is a Main Component of the Market
    • 5.2.1. NiQuitin/Nicabate/NicoDerm CQ (GSK)
    • 5.2.2. Nicorette (Johnson & Johnson/GSK)
    • 5.2.3. Nicotinell (Novartis)
    • 5.2.4. Other NRT Products
  • 5.3. Champix/Chantix (Varenicline, Pfizer)
    • 5.3.1. Champix/Chantix Sales Performance, 2012-2023
    • 5.3.2. Champix/Chantix May Help in Treating Other Addictions
  • 5.4. Zyban (Bupropion, GSK)
    • 5.4.1. Zyban Sales Forecast, 2012-2023
  • 5.5. Tabex - One to Watch Out For
  • 5.6. Other Smoking Cessation Aids
    • 5.6.1. Smokeless Tobacco
      • 5.6.1.1. E-Cigarettes
      • 5.6.1.2. Snus/Snuff
      • 5.6.1.3. Gutkhas
    • 5.6.2. CigRx Dietary Supplement
    • 5.6.3. Dissolvable Tobacco
    • 5.6.4. Behavioural Therapy

6. Smoking Cessation R&D Pipeline Analysis

  • 6.1. Nicotine Vaccines: Hype or Hope?
    • 6.1.1. TA-Nic (Celtic Pharma)
    • 6.1.2. Niccine (Independent Pharmaceutica AB)
    • 6.1.3. SEL-068 (Selecta Biosciences)
  • 6.2. Monoamine Oxidase Inhibitors
  • 6.3. Cannabinoid Receptor-1 Antagonists
  • 6.4. Dopamine D3 Antagonists
  • 6.5. Opiate Antagonists
  • 6.6. ARD-1600 (Aradigm)
  • 6.7. EMB-001(Embera NeuroTherapeutics)
  • 6.8. Meclizine (Duke University/Philip Morris Products)
  • 6.9. Other Smoking Cessation Aids Under Development
    • 6.9.1. X22TM (22nd Century Group)
    • 6.9.2. Other Developments

7. Smoking Cessation Industry: Qualitative Analyses, 2013-2023

  • 7.1. The Smoking Cessation Market was Dominated by Four Companies, But for How Long?
  • 7.2. SWOT and STEP Analysis of the Smoking Cessation Market
    • 7.2.1. Strengths of the Smoking Cessation Industry
      • 7.2.1.1. Innovation in Smoking Cessation Therapies
      • 7.2.1.2. Innovative Marketing
      • 7.2.1.3. Support Plans and Web 2.0 Technology in Combination with Pharmacotherapy
      • 7.2.1.4. OTC Switching
      • 7.2.1.5. Widespread Coverage of Smoking Cessation Products
    • 7.2.2. Weaknesses of the Smoking Cessation Industry
      • 7.2.2.1. Drugs Do Not Replace the Tactile and Oral Sensations Obtained from Smoking
      • 7.2.2.2. Currently-Marketed Smoking Cessation Therapies - Relapse Rate
      • 7.2.2.3. Concerns Regarding the Development of Addiction to NRTs
    • 7.2.3. Opportunities for the Smoking Cessation Industry
      • 7.2.3.1. Smoking is Prevalent Worldwide and Slowly Increasing
      • 7.2.3.2. Countries with Untapped Smoking Cessation Market Potential
      • 7.2.3.3. Growth of Emerging-Economy Smoking Cessation Markets
      • 7.2.3.4. Health Effects of Tobacco
      • 7.2.3.5. Economic and Social Impact of Tobacco on Society
      • 7.2.3.6. Framework Convention on Tobacco Control (FCTC)
      • 7.2.3.7. Government-Sponsored Smoking Cessation Programmes
      • 7.2.3.8. Increasing Tobacco Taxes
      • 7.2.3.9. Smoking Bans
      • 7.2.3.10. Warning Information on Tobacco Products
      • 7.2.3.11. Bans on Tobacco Advertising, Promotion and Sponsorship
      • 7.2.3.12. Upcoming Launch of Tabex
    • 7.2.4. Threats to the Smoking Cessation Industry
      • 7.2.4.1. Concern over Side-Effects of Smoking Cessation Drugs
      • 7.2.4.2. Lack of Reimbursement for Smoking Cessation Therapies
      • 7.2.4.3. Traditional Smokeless Tobacco
      • 7.2.4.4. The E-Cigarette

8. Research Interviews

  • 8.1. Interview with Dr Vladimir Kosev, Director Strategic Business Development, Sopharma
    • 8.1.1. On Sopharma's Geographical Focus
    • 8.1.2. On the Availability of Tabex
    • 8.1.3. On the Efficacy of Tabex in Comparison to Other Products
    • 8.1.4. On Any Other Points of Interest
  • 8.2. Interview with Mr Rick Stewart, CEO, Extab Corporation
    • 8.2.1. On Tabex's Release
    • 8.2.2. On Tabex vs. Other Smoking Cessation Treatments
    • 8.2.3. On the High Prices of Smoking Cessation Products Reducing Revenues in Poorer Nations
    • 8.2.4. On the Future Direction of the Industry
    • 8.2.5. On Any Other Points of Interest
  • 8.3. Interview with Mr Trevor Van Meirlo, CEO, Evolution Health Systems
    • 8.3.1. Unmet Needs
    • 8.3.2. Major Areas of Focus
    • 8.3.3. Smoking Cessation R&D Pipeline
    • 8.3.4. Opportunities for Revenue Growth
    • 8.3.5. Market Drivers
  • 8.4. Interview with Dr Peter Hajek, Director of Tobacco Dependence Research Unit, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, University of London
    • 8.4.1. Unmet Needs
    • 8.4.2. Major Areas of Focus and R&D Pipeline
    • 8.4.3. Opportunities for Revenue Growth
    • 8.4.4. Market Drivers

9. Conclusions of the Study

  • 9.1. Smoking is the Main Cause of Preventable Deaths Worldwide
  • 9.2. Smoking Cessation Medicines Have Promising Therapeutic and Commercial Potential from 2013 to 2023
  • 9.3. World Smoking Cessation Market: Prospects to 2023
  • 9.4. Market Drivers
  • 9.5. Leading and Emerging Smoking Cessation Markets
  • 9.6. Concluding Remarks

List of Tables

  • Table 3.1: World Smoking Cessation Market Forecast ($m), 2012-2023
  • Table 3.2: World Smoking Cessation Market Drivers and Restraints, 2012-2023
  • Table 3.3: Smoking Cessation Drug Market Forecast ($m) by Type of Sales, 2012-2023
  • Table 3.4: Over-The-Counter Smoking Cessation Market Forecast ($m), 2012-2023
  • Table 3.5: OTC Smoking Cessation Market Drivers and Restraints, 2012-2023
  • Table 3.6: Prescription (Rx) Smoking Cessation Market Forecast ($m), 2012-2023
  • Table 3.7: Prescription Smoking Cessation Drivers and Restraints, 2012-2023
  • Table 3.8: Smoking Cessation Market Forecasts by Drug Type ($m), 2012-2023
  • Table 3.9: Nicotine Replacement Therapy Market Forecast ($m), 2012-2023
  • Table 3.10: Nicotine Replacement Therapy Drivers and Restraints, 2012-2023
  • Table 3.11: NRPA Market Forecast ($m), 2012-2023
  • Table 3.12: NRPA Drivers and Restraints, 2012-2023
  • Table 3.13: Antidepressants Market Forecast ($m), 2012-2023
  • Table 3.14: Antidepressants Market Drivers and Restraints, 2012-2023
  • Table 4.1: Smoking Cessation Drugs Market Forecast ($m) by Leading Countries, 2012-2023
  • Table 4.2: Smoking Cessation Drugs Market Forecast ($m) & Market Shares (%) by Leading Countries, 2012
  • Table 4.3: US Smoking Cessation Drugs Market Forecast ($m), 2012-2023
  • Table 4.4: US Smoking Cessation Market Drivers and Restraints, 2012-2023
  • Table 4.5: Japanese Smoking Cessation Drugs Market Forecast ($m), 2012-2023
  • Table 4.6: Japanese Smoking Market Cessation Drugs Drivers and Restraints, 2012-2023
  • Table 4.7: EU5 Smoking Cessation Market Forecasts ($m), 2012-2023
  • Table 4.8: EU-5 Smoking Cessation Market Drivers and Restraints, 2012-2023
  • Table 4.9: UK Smoking Cessation Market Forecast ($m), 2012-2023
  • Table 4.10: French Smoking Cessation Market Forecast ($m), 2012-2023
  • Table 4.11: Spanish Smoking Cessation Market Forecast ($m), 2012-2023
  • Table 4.12: Italian Smoking Cessation Market Forecast ($m), 2012-2023
  • Table 4.13: German Smoking Cessation Market Forecast ($m), 2012-2023
  • Table 4.14: BRIC Smoking Cessation Market Forecasts ($m), 2012-2023
  • Table 4.15: BRIC Smoking Cessation Drugs Drivers and Restraints, 2012-2023
  • Table 4.16: Brazilian Smoking Cessation Market Forecasts ($m), 2012-2023
  • Table 4.17: Russian Smoking Cessation Market Forecasts ($m), 2012-2023
  • Table 4.18: Indian Smoking Cessation Market Forecast ($m), 2012-2023
  • Table 4.19: Chinese Smoking Cessation Market Forecast ($m), 2012-2023
  • Table 5.1: Top 5 Smoking Cessation Drugs' Sales ($m) and Market Shares (%), 2012
  • Table 5.2: Leading Smoking Cessation Brands: Sales Forecasts ($m), 2012-2023
  • Table 5.3: Nicotine Replacement Therapy Types, 2012
  • Table 5.4: NiQuitin /Nicabate/NicoDerm CQ NRT Brands, 2012
  • Table 5.5: NiQuitin/Nicabate/NicoDerm CQ Sales Forecast ($m), 2012-2023
  • Table 5.6: NiQuitin/Nicabate/NicoDerm CQ Drivers and Restraints, 2012-2023
  • Table 5.7: Nicorette NRT Brands, 2012
  • Table 5.8: Nicorette Sales Forecast ($m), 2012-2023
  • Table 5.9: Nicorette Drivers and Restraints, 2012-2023
  • Table 5.10: Nicotinell Sales Forecast ($m), 2012-2023
  • Table 5.11: Nicotinell Drivers and Restraints, 2012-2023
  • Table 5.12: Champix/Chantix Sales Forecast ($m), 2012-2023
  • Table 5.13: Champix/Chantix Drivers and Restraints, 2012-2023
  • Table 5.14: Zyban Sales Forecast ($m), 2012-2023
  • Table 5.15: Zyban Drivers and Restraints 2012-2023
  • Table 5.16: Tabex Sales Forecast ($m), 2012-2023
  • Table 5.17: Tabex Drivers and Restraints, 2012-2023
  • Table 6.1: Smoking Cessation R&D Pipeline: Some Leading Product Candidates, 2013
  • Table 6.2: Smoking Cessation R&D Pipeline: Apparent Disappointments
  • Table 7.1: Leading Companies in the Smoking Cessation Drugs Market, by Revenues ($m) and Market Share (%), 2012
  • Table 7.2: Leading Companies in the Smoking Cessation Drugs Market, by Revenues ($m) and Market Share (%), 2023
  • Table 7.3: Other Companies Operating in the Smoking Cessation Industry
  • Table 7.4: SWOT Analysis of the Industry and Market, 2012-2023
  • Table 7.5: STEP Analysis of the Industry and Market, 2012-2023
  • Table 9.1: Smoking Cessation Drug Market Forecast ($m) and Market Shares (%) by OTC and Rx, 2013, 2017 & 2023
  • Table 9.2: Smoking Cessation Drug Market Forecast ($m) and Market Shares (%) by Drug Type, 2013, 2017 & 2023
  • Table 9.3: Smoking Cessation Drug Market Forecast ($m) and Market Shares (%) by Leading Countries, 2013, 2017 & 2023

List of Figures

  • Figure 2.1: Smoking-Related Health Disorders
  • Figure 3.1: World Smoking Cessation Market Forecast ($m), 2012-2023
  • Figure 3.2: Smoking Cessation Market Shares (%) by Type of Sale, 2012
  • Figure 3.3: OTC Smoking Cessation Drugs Market Forecast ($m), 2012-2023
  • Figure 3.4: Rx Smoking Cessation Market Forecast ($m), 2012-2023
  • Figure 3.5: Smoking Cessation Market Shares (%) by Drug Type, 2012
  • Figure 3.6: NRT Market Forecast ($m), 2012-2023
  • Figure 3.7: NRPA Market Forecast ($m), 2012-2023
  • Figure 3.8: Antidepressants for Smoking Cessation: Market Forecast ($m), 2012-2023
  • Figure 4.1: Smoking Cessation Drugs Market Shares (%) by Leading Countries, 2012
  • Figure 4.2: Smoking Cessation Drugs Market Shares (%) by Leading Countries, 2017
  • Figure 4.3: Smoking Cessation Drugs Market Shares (%) by Leading Countries, 2023
  • Figure 4.4: US Smoking Cessation Drugs Market Forecast ($m), 2012-2023
  • Figure 4.5: Japanese Smoking Cessation Drugs Market Forecast ($m), 2012-2023
  • Figure 4.6: EU5 Smoking Cessation Market Forecasts ($m), 2012-2023
  • Figure 4.7: UK Smoking Cessation Market Forecast ($m), 2012-2023
  • Figure 4.8: French Smoking Cessation Market Forecast ($m), 2012-2023
  • Figure 4.9: Spanish Smoking Cessation Market Forecast ($m), 2012-2023
  • Figure 4.10: Italian Smoking Cessation Market Forecast ($m), 2012-2023
  • Figure 4.11: German Smoking Cessation Market Forecast ($m), 2012-2023
  • Figure 4.12: BRIC Smoking Cessation Market Forecast ($m), 2012-2023
  • Figure 4.13: Brazilian Smoking Cessation Market Forecast ($m), 2012-2023
  • Figure 4.14: Russian Smoking Cessation Market Forecast ($m), 2012-2023
  • Figure 4.15: Indian Smoking Cessation Market Forecast ($m), 2012-2023
  • Figure 4.16: Chinese Smoking Cessation Market Forecast ($m), 2012-2023
  • Figure 5.1: Top 5 Smoking Cessation Drugs: Market Shares (%), 2012
  • Figure 5.2: NiQuitin/Nicabate/NicoDerm CQ Sales Forecast ($m), 2012-2023
  • Figure 5.3: Nicorette Sales Forecast ($m), 2012-2023
  • Figure 5.4: Nicotinell Sales Forecast ($m), 2012-2023
  • Figure 5.5: Champix/Chantix Sales Forecast ($m), 2012-2023
  • Figure 5.6: Zyban Sales Forecast ($m), 2012-2023
  • Figure 5.7: Tabex Sales Forecast ($m), 2012-2023
  • Figure 7.1: Leading Companies in the Smoking Cessation Drugs Industry by Market Share (%), 2012
  • Figure 7.2: Leading Companies in the Smoking Cessation Drugs Industry by Market Share (%), 2023
  • Figure 9.1: Smoking Cessation Drugs: World Market Revenue Forecast ($m), 2012-2023
  • Figure 9.2: Smoking Cessation Drug Market by Leading Countries: Market Shares (%), 2013, 2017 & 2023

Companies Listed

  • 22nd Century Group
  • Action on Smoking on Health (ASH)
  • Advent Life Sciences
  • Alkermes
  • American Heart Association (AHA)
  • American Lung Association (ALA)
  • Aradigm
  • Australian Therapeutic Goods Administration
  • BGP Group
  • Boots
  • Cochrane Collaboration
  • Cambrex
  • Campaign for Tobacco-Free Kids
  • Cancer Centre and Institute of Oncology
  • Ceejay Healthcare
  • Celtic Pharma
  • Centers for Disease Control and Prevention (CDC)
  • Cephalon
  • China National Tobacco Corporation
  • CN Creative
  • Cytos Biotechnology
  • Duke University
  • Embera NeuroTherapeutics
  • European Medicines Agency (EMA)
  • Evolution Health Systems
  • Evotec
  • Excelsa Pharma
  • Extab Corporation
  • Fertin Pharma A/S
  • Food and Drug Administration (US FDA)
  • GlaxoSmithKline (GSK)
  • Haihang Industry Company
  • Health Canada
  • Independent Pharmaceutica AB
  • Japanese Ministry of Health, Labour and Welfare (MHLW)
  • Japan Tobacco
  • Johnson & Johnson
  • Karolinska Institutet
  • LEO Pharma
  • LSU Health Sciences Center - Shreveport
  • Mayo Clinic
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Nabi Biopharmaceuticals
  • National Cancer Institute (NCI)
  • National Health Service (UK NHS)
  • National Institute for Health and Clinical Excellence (UK NICE)
  • National Institute on Drug Abuse (NIDA)
  • Next Safety
  • Nicobrand
  • Niconovum AB
  • Nicoventures
  • Novartis
  • Nulife
  • Nu-Mark
  • Perrigo
  • Pfizer
  • Philip Morris Products S.A
  • Queen Mary University of London
  • Revolymer
  • R.J. Reynolds Tobacco Company
  • Rock Creek Pharmaceuticals
  • Roche
  • Ruyan
  • Sanofi
  • Selecta Biosciences
  • Sopharma
  • Spanish Ministry of Health, Social Services and Equality
  • Star Scientific
  • Taj Pharmaceuticals
  • Target Corporation
  • Teva Pharmaceutical Industries
  • Tobacco Dependence Research Unit, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry
  • Tobacco Manufacturers Association
  • University College London (UCL)
  • UK Centre for Tobacco Control Studies
  • Walmart
  • Wolfson Institute of Preventive Medicine
  • World Bank
  • World Health Organization (WHO)
  • Zenara
Back to Top